Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078446 | 0.85 | AR (0.47) | ARKCNH2CTSS | |
| SCHEMBL3068258 | 0.78 | TMEM97 (0.47) | ARKCNH2AXL | |
| SCHEMBL2268879 | 0.76 | HTT (0.51) | OPRL1OPRM1OPRK1ARKCNH2 | |
| SCHEMBL3066724 | 0.73 | AR (0.54) | ARKCNH2 | |
| SCHEMBL24592361 | 0.72 | AR (0.57) | ARKCNH2 | |
| SCHEMBL24592309 | 0.70 | AR (0.64) | ARKCNH2 | |
| SCHEMBL16719380 | 0.70 | OPRL1 (0.64) | OPRL1OPRM1OPRK1HSD11B1AXL | |
| SCHEMBL17857690 | 0.70 | OPRL1 (0.65) | OPRL1OPRM1OPRK1CTSSHSD11B1 | |
| SCHEMBL25787927 | 0.70 | OPRL1 (0.65) | OPRL1OPRM1OPRK1CTSSHSD11B1 | |
| SCHEMBL26911658 | 0.69 | OPRL1 (0.58) | OPRL1OPRM1OPRK1HSD11B1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | claimed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | claimed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | claimed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | OPRL1 232/4885OPRM1 494/4885OPRK1 120/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | OPRL1 226/4885OPRM1 436/4885OPRK1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.